Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Nilotinib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth.
PURPOSE: This phase II trial is studying how well nilotinib works in treating patients with
newly diagnosed chronic phase chronic myelogenous leukemia.